Investors

Within a year of its inception, ActoGeniX raised €23 million (approximately US$35 million), €20 million of which was obtained through a Series A equity round, one of the largest among European biotech start-ups.

In July 2007, ActoGeniX announced the approval of a €3 million (approximately US$4.4 million) grant from the Institute for Promotion of Innovation by Science and Technology in Flanders (IWT), to support its innovative therapeutic drug development activities during a two-year period.

In the first quarter of 2009, the Company announced that it had raised an additional €15.5 million (approximately US$20 million) from its strong syndicate of life sciences investors, including new investor Biovest (Belgium) as well as the existing investors.

In the second quarter of 2009, ActoGeniX was awarded a €0.9 million grant (US$1.3 million) by IWT, to support the clinical development of AG013, a novel ActoBiotic™ for the treatment of oral mucositis in cancer patients.

ActoGeniX's syndicate of experienced life sciences investors includes companies such as Gimv, Biotech Fund Flanders, Baekeland Fund and BioVest (Belgium), LSP and Aescap Venture (The Netherlands) and Ventech (France).